With peptide use gaining traction in wellness and longevity settings, providers face a growing challenge of navigating a complex and state-dependent legal landscape. Patients often view these therapies as cutting-edge tools for metabolic support, recovery, immune modulation, and anti-aging strategies. Yet as demand rises, so does regulatory scrutiny. While federal law determines how peptides are classified, state law ultimately determines whether they may be prescribed, administered, or compounded in a wellness setting.
This article is part of a four-part series examining the legal framework surrounding peptide programs in medical spas and wellness practices, including:
- Part 1 – What Are Peptides and How Are They Administered?
- Part 2 – Does the Corporate Practice of Medicine Apply to Peptides?
- Part 3 – How State Laws That Impact Peptide Use in Wellness Practices
How Does Federal Classification Affect State Regulations?
Peptides are not classified as supplements when used to diagnose, treat, or prevent disease. They are prescription drugs and, by definition, part of the practice of medicine. That classification alone triggers state-level oversight.
From there, the analysis becomes more nuanced. Certain peptides hold Federal Drug Administration (“FDA”) approval for specific, narrowly defined indications. In other situations, an FDA-approved peptide may be prescribed for a use that falls outside its labeled indication, which constitutes off-label prescribing. And at the far end of the regulatory spectrum are peptides that have never received FDA approval for any human use at all. Although the FDA determines approval status, state medical and pharmacy laws govern how those substances may be accessed and delivered in clinical practice. As a result, federal classification does not answer the more practical question for wellness centers: Can we legally offer this here?
State Restrictions for Unapproved Peptides
The answer often depends on the peptide’s approval status and the state in which the practice operates. Many states take a restrictive view of all drugs that have not received FDA approval, including peptides.
In jurisdictions such as Washington and New Jersey, unapproved peptides may only be accessed through clearly defined investigational pathways. Those pathways can include Institutional Review Board (“IRB”) oversight, structured research protocols, and compliance with Investigational New Drug (“IND”) requirements. Outside of those frameworks, prescribing or administering an unapproved peptide may expose providers to board discipline and broader regulatory consequences.
Importantly, the fact that a peptide is widely marketed or readily available online does not make it legally permissible under state law. Regulatory boards will look to statutory authority and professional standards, not industry trends.
How State Licensing Rules Shape Peptide Prescription and Administration
Even when a peptide is legally permissible, another layer of state law comes into play concerning who may prescribe and who may administer it.
Scope of practice rules vary widely across jurisdictions. Some states restrict prescribing authority to physicians for certain drug categories. Others allow physician assistants and nurse practitioners broader autonomy but impose collaboration or supervisory requirements. Registered nurses operate under delegation frameworks that may limit independent action, particularly for injectable therapies. The route of administration also matters. Injectable peptides often carry stricter supervision requirements than oral or topical formulations. As a result, compliance analysis must address not only the substance itself but also how it is delivered and by whom.
Why Right to Try Laws Rarely Apply to Wellness Practices
Right to Try laws are state and federal statutes designed to allow certain patients with intractable or life‑threatening illnesses to access investigational drugs that have not yet received FDA approval, outside of clinical trials. Practices sometimes look to Right to Try laws as a potential pathway for offering investigational therapies. However, those statutes are limited in scope and typically apply only to patients with life-threatening or chronic conditions who have exhausted approved treatment options.
Because most peptide services in wellness and longevity settings are elective and not tied to terminal diagnoses, Right to Try rarely provides a viable legal foundation. Attempting to rely on it outside its intended purpose can increase, rather than reduce, regulatory exposure.
Complementary and Alternative Medicine Rules for Peptides
Certain states provide limited flexibility through complementary and alternative medicine frameworks. Under these models, providers may have discretion to offer therapies outside conventional standards when there is reasonable evidence that the potential benefit of a treatment outweighs its risk. Complementary and alternative medicine regulations require that patients receive full disclosure regarding the treatment.
However, these pathways do not override federal prohibitions or permit the use of high-risk investigational substances that fall outside lawful access channels. Each state’s statutory language must be reviewed carefully before relying on this approach.
Off-Label Peptide Use Requires Scientific Support and Structured Consent
When a peptide is FDA-approved but used for a different indication, the analysis shifts to off-label prescribing. Off-label use is legally recognized, but it carries defined responsibilities. A provider must exercise independent medical judgment supported by a credible scientific rationale. Peer-reviewed literature, established clinical guidelines, or other reliable data should support the decision. Equally important, the patient must receive clear and thorough informed consent explaining the off-label nature of the treatment, the risks and benefits, and available alternatives. Without that foundation, regulators may characterize the therapy as experimental. In a wellness environment, where marketing language can blur clinical distinctions, careful documentation and patient communication become particularly important.
Why Do Unapproved Peptides Carry High Legal Risk?
The risk profile increases significantly when a peptide is not approved for any human use. These substances have not completed the FDA’s testing and approval process, which means safety and efficacy data may be limited or nonexistent.
In most circumstances, wholly unapproved drugs may only be accessed through IND applications, IRB-supervised research, or formal expanded access programs. Using them outside of those channels can trigger state board investigations, allegations of unprofessional conduct, and malpractice exposure.
The same is true for peptides labeled “not for human consumption,” meaning they are unregulated and potentially unsafe. It is common for unapproved peptides to be marketed in this manner but it does not change the regulatory risk profile. In fact, the labeling may serve as proof that the provider knew the peptides were inappropriate to prescribe. These “Research Chemicals” should never be prescribed to patients. For wellness centers, the takeaway is straightforward: if a peptide is unapproved, the legal pathway for offering it is typically far narrower than marketing materials suggest.
Why Peptide Compliance Matters
Peptides can support patient engagement and differentiate a wellness practice in a competitive marketplace. Still, regulatory alignment must drive the structure of the service line.
Before incorporating a peptide into patient care, practices should evaluate its FDA approval status; determine whether the proposed use is on-label, off-label, or investigational; review state-specific restrictions on experimental therapies; and confirm each state’s scope of practice and supervision requirements. Compounding limitations and informed consent protocols should also be addressed at the outset. Demand does not create authorization. State law does. Aligning peptide services with that reality protects both patients and the long-term viability of the practice.
How Practices Can Stay Compliant with State Peptide Laws
Peptide compliance is not determined by marketing trends or patient demand. It is shaped by approval status, state law, and the professional obligations imposed on licensed providers. Before integrating any peptide into a wellness setting, practices should work through the following considerations:
Assess Approval Status and Intended Use:
Confirm whether the peptide is FDA-approved, will be used on-label, prescribed off-label with appropriate scientific support, or considered investigational. Peptides not approved for any human use are generally limited to IND or expanded access pathways and present significantly higher legal risk if used outside those channels.
Evaluate State-Specific Restrictions:
Determine whether your state permits the peptide at issue and under what framework. Some states restrict unapproved peptides to investigational pathways such as IRB oversight or formal research protocols. Right to Try statutes are narrow and rarely applicable in wellness settings.
Confirm the Scope of Practice and Supervision Requirements
Review state laws governing who may prescribe and administer the peptide. Ensure physicians, NPs, PAs, and RNs operate within delegation, collaboration, and supervision requirements, taking into account the route of administration and applicable board regulations.
Risks of Off-Label and Experimental Peptide Use
Practices should understand the risks associated with prescribing off-label and obtain proper patient consents.
ByrdAdatto Can Help You Navigate State Peptide Laws
Incorporating peptides into a wellness or longevity practice can expand services and strengthen patient engagement, but the legal framework governing their use is detailed and varies by jurisdiction. Questions surrounding approval status, investigational access, delegation authority, and provider oversight can quickly create exposure if not addressed proactively, and you should not have to navigate that terrain alone.
Our legal team works with wellness centers and med spas to evaluate peptide offerings, analyze state-specific restrictions, structure compliant delegation models, and implement informed consent and documentation protocols that reduce exposure. Contact ByrdAdatto to integrate peptide services in a way that supports your growth goals while maintaining compliance at every stage.
